Alisertib (MLN8237)

目录号:S1133

Alisertib (MLN8237) Chemical Structure

Molecular Weight(MW): 518.92

Alisertib (MLN8237)是一种选择性Aurora A抑制剂,无细胞试验中IC50为1.2 nM,作用于Aurora A比作用于Aurora B选择性强200倍以上。Phase 3。

规格 价格 库存 购买数量  
RMB 1375.12 现货
RMB 983.87 现货
RMB 1725.78 现货
RMB 5505.84 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献49篇:

客户使用该产品的12个实验数据:

  • Inhibition of Aurka kinase activity by MLN8237 impairs expression of pluripotency genes in CCE cells as measured by qRT-PCR. All values shown are mean ?SEM for n=3. The level of phosphorylated H3(S10) (p-H3(S10)), an Aurka phosphorylation target site, is decreased in MLN8237-treated samples.

    Cell Stem Cell 2012 11, 179-94. Alisertib (MLN8237) purchased from Selleck.

    Recruitment of clathrin to the mitotic spindle is controlled by phosphorylation of TACC3 by Aurora-A kinase. Representative micrographs of HEK293 cells incubated with 0.3 μM MLN8237 for 40 min. Cells were fixed and stained as indicated.

    EMBO J 2012 30, 906-19. Alisertib (MLN8237) purchased from Selleck.

  • Tissue levels of 53BP1, a-tubulin, IkB-a and IL-6 in an Hs294T xenograft treated with MLN8237 or vehicle control were visualized by immunofluorescence co-staining with DAPI. Representative micrographs are shown from triplicate experiments.

    EMBO Mol Med 2013 5(1), 149-66. Alisertib (MLN8237) purchased from Selleck.

    NUSAP mitotic phosphorylation at Ser 240 correlates with Aurora A activity. Protein samples of FLAG-NUSAP immunoprecipitated from I, M and MtMLN or with MtZM were analysed using LC-MS/MS, focusing on the predicted phosphorylated residue Ser 240. The histograms (A, B) show the calculated ratios based on peptides carrying the phosphorylated Ser 240 compared with all matched peptides containing this residue.

     

     

    EMBO reports 2010 11, 977-984. Alisertib (MLN8237) purchased from Selleck.

  • Aurora A inhibition rescues the PPP6C depletion phenotype. (A) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 or 20 nM MLN8237 or a solvent control for 15 min before lysis in phosphatase inhibitor containing buffer or fixation. Total lysates were analyzed by Western blotting. The red and black lines indicate the hosphorylated and nonphosphorylated forms of Aurora A. Fixed cells were stained using DAPI to detect DNA and antibodies to α-tubulin and Aurora A pT288. The intensity of pT288 staining was integrated using ImageJ over the spindle region defined by TPX2 staining and is plotted in the bar graph ( n = 4). Arrowheads indicate micronuclei. Bar, 5 µm. (B) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 nM MLN8237 or a solvent control for 24 h before fixation and staining with DAPI to detect DNA.

    J Cell Biol 2010 191, 1315-32. Alisertib (MLN8237) purchased from Selleck.

    D) Pharmacological inhibition of AURKA using alisertib led to downregulation of p-EIF4E (S209) and c-MYC proteins in FLO-1 and SK-GT-4 resistant cells, with or without RAD001 treatment.

    Clin Cancer Res, 2017, 23(14):3756-3768. Alisertib (MLN8237) purchased from Selleck.

  • Eg5 inhibition counteracts the induction of spindle pole fragmentation by Aurora-A inactivation. The protocol to inhibit Aurora-A by MLN8237 in cells progressing towards mitosis is depicted (time intervals not represented to scale). Control cultures were treated with solvent (DMSO) in the same time window. When indicated, MON was added 1 hour before harvesting. Note the absence of active phosphorylated (pThr288) Aurora-A (in red in IF panels) in cells treated with MLN8237. Upper histograms represent the percentage of all spindle and MT abnormalities in control and MLN8237-treated cultures (200 counted PM/M per condition in 2 experiments); the grey fraction of the histograms represents mitoses with spindle extrapoles, while other defects (monopolar or disorganised spindles, few and short MTs) are in white. Lower histograms and IF panels show that concomitant Eg5 inhibition by MON prevents MLN8237-induced spindle pole fragmentation (note the failure of centrosome migration reflecting Eg5 inactivation in lower IF panels). 200 PM/M per condition were counted in 2 experiments. Error bars represent s.d. **: p < 0.001, χ2 test. Red asterisks indicate significant differences with respect to DMSO controls, and black asterisks significant differences between Aurora-Ai mitoses with active or inactive Eg5. Scale bar: 10 μm

    Mol Cancer 2011 10, 131. Alisertib (MLN8237) purchased from Selleck.

    Alisertib inhibits AURKA and AURKB in a concentration-dependent manner. (a) Alisertib induces G 2 /M delay or genome reduplication. HeLa cells were exposed to buffer or the indicated concentrations of Alisertib. After 24 h, the cells were harvested and analyzed with flow cytometry. The positions of 2N, 4N and 8N DNA contents are indicated. (b) Alisertib delays mitotic exit or induces slippage. HeLa cells stably expressing histone H2B-GFP were exposed to buffer or the indicated concentrations of Alisertib. Individual cells were then tracked for 24 h with time-lapse microscopy. Each horizontal bar represents one cell (n ¼ 50). Key: light gray ¼ interphase; black ¼ mitosis (from DNA condensation to anaphase or mitotic slippage); dark gray ¼ interphase after mitotic slippage; truncated bars ¼ cell death. (c) Different concentrations of Alisertib are involved in delaying mitotic exit and inducing slippage. Live-cell imaging of cells treated with Alisertib was described in panel (b). The duration of mitosis (mean±90% confidence interval) and the percentage of cells that underwent mitotic slippage during the imaging period was quantified. (d) Alisertib promotes apoptosis in a concentration-dependent manner. HeLa cells were incubated with the indicated concentrations of Alisertib for 48 h. The cells were then harvested and analyzed with flow cytometry. (e) Concentration-dependent cytotoxicity of Alisertib. HeLa cells were cultured in the presence of the indicated concentrations of Alisertib for 48 h. The number of live and dead cells was analyzed with trypan blue exclusion assay. (f) Concentration-dependent suppression of long-term survival by Alisertib. HeLa cells were seeded on 60-mm culture plates and grown in the presence of 250 n M or 1 m M of Alisertib. After 24 h, the cells were washed gently and propagated in normal medium for another 10–12 days. Colonies were fixed and stained with crystal violet solution (examples of the plates are shown). Average±s.d. from three independent experiments. (g) Both AURKA and AURKB are inhibited by Alisertib.Mitotic HeLa cells were obtained by exposure to nocodazole for 16 h followed by mechanical shake off. The cells were incubated with the indicated concentrations of Alisertib for 2 h. Lysates were then prepared and activated phospho-AURKAThr288 and AURKBThr232were detected with immunoblotting. The asterisk indicates the position of an AURKB-like protein (the same throughout this study). Uniform loading was confirmed by immunoblotting for actin. In this assay, nocodazole and MG132 (a proteasome inhibitor) were added to prevent the cells from exiting mitosis. Accordingly, the total AURKA and AURKB levels remained constant throughout the experiment. (h) Alisertib prevents activation of AURKA and AURKB. HeLa cells were incubated with the indicated concentrations of Alisertib for 8 h. Nocodazole was then added for another 6 h to trap cells that entered mitosis. Lysates were prepared and analyzed with immunoblotting. Actin analysis was included to assess loading and transfer.

    Oncogene 2014 33, 3550-60. Alisertib (MLN8237) purchased from Selleck.

  • Inhibition of Aurora A (12.5 nM) by MLN8054 or MLN8237 was assessed in duplicate radiometric assays containing 100 μM [γ-32P] ATP and quantified by p81 phosphocellulose assay and scintillation counting. Kinase activity is reported as a percentage of control calculated from duplicate incubations containing 2.5% (v/v) DMSO. IC50 values represent the mean ±SEM calculated from two independent experiments.

     

     

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

    The effects of T217D and T217N Aurora A mutations were directly compared to WT Aurora A-expressing cells. Each well was treated with either DMSO or 500 nM MLN8054 (E), or 30 nM MLN8237 (F) on day one of the experiment and cells were cultured for 8 days, at which point they were fixed. For all colony assays, an area encompassing >90 % of the colonies per dish is shown. Similar results were seen in two independent duplicate experiments.

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

  • B, drug-treated cells were also stained with DAPI to visualize nuclear DNA and analyzed with a microscope equipped with a fluorescence digital CCD camera. Representative results are shown. Bar, 40 μm.

    J Biol Chem, 2017, 292(5):1910-1924. Alisertib (MLN8237) purchased from Selleck.

    C, Fry depletion decreases the level of Thr-210 phosphorylation of Plk1 on spindle poles. HeLa cells transfected with siRNAs were cultured in growth medium for 12 h and in thymidine-containing medium for 36 h. They were then released from thymidine arrest for 12 h before being fixed and stained with anti-Plk1 pT210 ( green) and anti-pericentrin (red) antibodies. DNA was stained with TO-PRO-3 ( blue ). For Aurora A inhibition, after release from thymidine block for 10 h, HeLa cells transfected with control siRNA were incubated for2h in medium containing MLN8237 (100 nM) and MG132 (10 μM). Magnified images of the white boxes are also shown. Scale bar ,5 μm.

    J Biol Chem 2012 287, 27670-81. Alisertib (MLN8237) purchased from Selleck.

产品安全说明书

Aurora Kinase抑制剂选择性比较

生物活性

产品描述 Alisertib (MLN8237)是一种选择性Aurora A抑制剂,无细胞试验中IC50为1.2 nM,作用于Aurora A比作用于Aurora B选择性强200倍以上。Phase 3。
特性 MLN8237 是第一个口服有效的小分子Aurora A激酶选择性抑制剂。
靶点
Aurora A [1]
(Cell-free assay)
1.2 nM
体外研究

MLN8237作用于Aurora A选择性比作用于结构相关的Aurora B 高200多倍,IC50为396.5 nM, 而对205种其他激酶则没有显著活性。[1] 0.5 μM MLN8237处理MM1.S和 OPM1 细胞,抑制 Aurora A磷酸化,而不影响 Aurora B调节的组蛋白H3磷酸化。MLN8237作用于多发性骨髓瘤(MM) 细胞系,显著抑制细胞增殖,IC50为0.003-1.71 μM。在BM 基质细胞,IL-6和 IGF-1 存在时,MLN8237作用于原代MM 细胞和MM细胞系,抗增殖活性比只有MLN8237单独作用时高很多。0.5 μM MLN8237 作用于原代MM细胞和细胞系,使G2/M 期细胞提高2到6倍,且显著诱导凋亡和衰老,涉及p53, p21 和p27的上调,及 PARP,caspase 3,和 caspase 9的裂解。此外, MLN8237和 Dexamethasone联用具有协同作用,具有强抗MM 功效, 而和Doxorubicin 及Bortezomib联用则具有另外的功能。[2] 0.5 μM MLN8237处理 FLO-1, OE19, 和OE33 食管腺癌细胞系,抑制集落形成,且显著提高多倍体细胞百分数,随后提高G1期细胞百分数,而与 Cisplatin (2.5 μM)联用则效果进一步提高,与单独用药相比,诱导产生更多, TAp73β, PUMA, NOXA, cleaved caspase-3, 和cleaved PARP。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HCT116 MoD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFm0cGMxNjVizszN M4rLXVczKGh? NID5RmRFVVOR NHXYWlFKSzVyPUCuNFQh|ryP NEj5VJkzPjF|Nk[4OC=>
LS174T MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fSTVAvPSEQvF2= NVXHSYZiPzJiaB?= MlPTSG1UVw>? NUDlbFlFUUN3ME2wMlA2KM7:TR?= MVKyOlE{PjZ6NB?=
T84 M3jsdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTMZpc1OC53IN88US=> MojpO|IhcA>? M1ThT2ROW09? NGPFWnFKSzVyPUCuNFkh|ryP NHzHTWgzPjF|Nk[4OC=>
LS180 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vE[|AvPSEQvF2= M371PFczKGh? NHPTfYRFVVOR NUD6V4hrUUN3ME2xJO69VQ>? M{HYNVI3OTN4Nki0
SW948 Mmq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\pZ|dKOC53IN88US=> NF7DS2w4OiCq MUPEUXNQ MYjJR|UxRTFizszN NEnLWZQzPjF|Nk[4OC=>
HCT15 MlrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDvNE42KM7:TR?= NED4To84OiCq NWHyb5RGTE2VTx?= MYXJR|UxRDBwNDFOwG0> MoXLNlYyOzZ4OES=
DLD-1 M13R[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEX1XZcxNjVizszN NHzJWmM4OiCq MW\EUXNQ NVXFTWp3UUN3MEywMlgh|ryP NVG1XYJwOjZzM{[2PFQ>
MIP-101 Ml[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrXV2tXOC53IN88US=> Mmm1O|IhcA>? MV;EUXNQ MlO3TWM2OD1zIN88US=> NWXxUHgxOjZzM{[2PFQ>
SNU1544 NHHpfolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlH0NE42KM7:TR?= MkS0O|IhcA>? MlrYSG1UVw>? Ml;sTWM2OD1zIN88US=> NXHwRndoOjZzM{[2PFQ>
OCI-Ly10 Mni0R5l1d3SxeHnjJGF{e2G7 M{e4T|czKGh? NFnh[VBFVVOR MnzuTWM2OD1yLkC1PEDPxE1? NXXoW|M4OjV6N{izN|E>
SU-DHL2 Mm[0R5l1d3SxeHnjJGF{e2G7 NWqyXmJjPzJiaB?= NFXJ[41FVVOR M2DQWmlEPTB;MD6wNUDPxE1? NIrjXJEzPTh5OEOzNS=>
OCI-LY7 M{n3dGN6fG:2b4jpZ{BCe3OjeR?= NHXDN4Y4OiCq MV7EUXNQ M2HycmlEPTB;MD6wPFEh|ryP MmXKNlU5Pzh|M{G=
SU-DHL6 M1jhRmN6fG:2b4jpZ{BCe3OjeR?= M1rLU|czKGh? M3ztb2ROW09? Mlu3TWM2OD1yLkS4NkDPxE1? M1OzPFI2QDd6M{Ox
Jeko-1 NF7mbpBEgXSxdH;4bYMhSXO|YYm= NXnCOWpDPzJiaB?= NV7LZ2ljTE2VTx?= NUH2ZXZNUUN3ME2wMlAzQSEQvF2= MWOyOVg4QDN|MR?=
JVM-2 MX;DfZRwfG:6aXOgRZN{[Xl? MmftO|IhcA>? Mn;NSG1UVw>? M2HkZmlEPTB;MD6wNUDPxE1? NEmzdpYzPTh5OEOzNS=>
Rec-1 M{X6UGN6fG:2b4jpZ{BCe3OjeR?= NGPXb4k4OiCq M4P4ZWROW09? MX\JR|UxRTBwMEi3JO69VQ>? Mk\6NlU5Pzh|M{G=
Z-138 NILVVYpEgXSxdH;4bYMhSXO|YYm= NHzHSWY4OiCq M1zSWmROW09? MlvaTWM2OD1yLkCxN{DPxE1? NH7TVm8zPTh5OEOzNS=>
H9 MU\DfZRwfG:6aXOgRZN{[Xl? M1X4bVczKGh? M4DDNGROW09? M16wTmlEPTB;MD62JO69VQ>? NEXuOnczPTh5OEOzNS=>
HH NUDwNVZqS3m2b4TvfIlkKEG|c3H5 NHTEUFc4OiCq NF\te|BFVVOR M2T1VmlEPTB;MD63JO69VQ>? M1G1dFI2QDd6M{Ox
DND41 NWLnTI9mS3m2b4TvfIlkKEG|c3H5 NVPpT4FSPzJiaB?= MlPySG1UVw>? MULJR|UxRTBwMTFOwG0> NEH0UZczPTh5OEOzNS=>
CCL119 MVXDfZRwfG:6aXOgRZN{[Xl? MkL3O|IhcA>? M1fxc2ROW09? M4HGUWlEPTB;MD6wOlIh|ryP NVP4[otOOjV6N{izN|E>
J.Cam 1.6 MYrDfZRwfG:6aXOgRZN{[Xl? MorCO|IhcA>? MlrmSG1UVw>? MnLGTWM2OD1yLkGwOUDPxE1? NXLvU4RROjV6N{izN|E>
Sup-T1 MUnDfZRwfG:6aXOgRZN{[Xl? MUW3NkBp NGrxVVRFVVOR NY\3eVFHUUN3ME2yMlE1OiEQvF2= MX6yOVg4QDN|MR?=
Tib 152 MUTDfZRwfG:6aXOgRZN{[Xl? MomxO|IhcA>? MUDEUXNQ MUPJR|UxRTBwODFOwG0> Mo\uNlU5Pzh|M{G=
MCF7 NVzkW4ZHTnWwY4Tpc44hSXO|YYm= M3P5blUh|ryP M1HRd|I1KGh? NUDXR3FrTE2VTx?= NFLWNpJKdmS3Y3XzJGczN01iYYLy[ZN1 NV:1cVFzOjV6M{S0NFE>
MDA-MB-231 NIjRWlVHfW6ldHnvckBCe3OjeR?= M1LwcVUh|ryP M3T1T|I1KGh? MoHMSG1UVw>? NXK2[WlwUW6mdXPld{BIOy:PIHHydoV{fA>? MlW3NlU5OzR2MEG=
MCF7 MlLQSpVv[3Srb36gRZN{[Xl? M2\OXFUh|ryP M4DPfFI1KGh? MYDEUXNQ MV3E[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZiQ1TLNU9ETEN{ MmnaNlU5OzR2MEG=
MCF7 MXjGeY5kfGmxbjDBd5NigQ>? MV61JO69VQ>? MX2yOEBp NVKxRVFnTE2VTx?= NEe2flhF\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gR2RMOg>? NHf5fW4zPTh|NESwNS=>
MCF7 NV\id5R{TnWwY4Tpc44hSXO|YYm= MYO1JO69VQ>? MnPPNlQhcA>? MkPtSG1UVw>? MVHE[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZiY4njcIlvKEJz Mn\NNlU5OzR2MEG=
MCF7 MV;GeY5kfGmxbjDBd5NigQ>? NX25S5VZPSEQvF2= NY\1SYVSOjRiaB?= MnftSG1UVw>? MYnJcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZicEKxJHdi\jFxQ3nwNS=> NI\4cnozPTh|NESwNS=>
MCF7 NIm3bWVHfW6ldHnvckBCe3OjeR?= NH3JXJA2KM7:TR?= NHzueoszPCCq M2DkPGROW09? NXGyU4ZFUW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJJAzPyCNaYCx MVWyOVg{PDRyMR?=
MDA-MB-231 MVrGeY5kfGmxbjDBd5NigQ>? MnfpOUDPxE1? NXPtbJl5OjRiaB?= MUPEUXNQ NWPT[G16TGWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJGNFUzFxQ1TDNi=> NYX5b2prOjV6M{S0NFE>
MDA-MB-231 MlvKSpVv[3Srb36gRZN{[Xl? MlvtNUDPxE1? NHnYTI0zPCCq M4TZTGROW09? NHjDN49KdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gR2RMOg>? NGDWWHUzPTh|NESwNS=>
MDA-MB-231 NXuxcVh{TnWwY4Tpc44hSXO|YYm= MoD4OUDPxE1? Ml;lNlQhcA>? NFnwTnRFVVOR MXvE[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZiY4njcIlvKEJz MX:yOVg{PDRyMR?=
MDA-MB-231 NWjaVGFmTnWwY4Tpc44hSXO|YYm= M3fabVUh|ryP MYmyOEBp NHPkXpNFVVOR MmnrTY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIICyNUBY[WZzL1PpdFE> MUWyOVg{PDRyMR?=
MDA-MB-231 NFrjNIpHfW6ldHnvckBCe3OjeR?= Mom3OUDPxE1? MojkNlQhcA>? NXy0cWs5TE2VTx?= MkHMTY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIICyO{BMcXBz NGjM[2EzPTh|NESwNS=>
MDA-MB-231 MVrGeY5kfGmxbjDBd5NigQ>? Mm\aOUDPxE1? MXyyOEBp NUH6Z|M4TE2VTx?= NYT1PFIxUW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJJA2Ow>? NVv5RXN3OjV6M{S0NFE>
MCF7 MoPzRZBweHSxc3nzJGF{e2G7 M4PMfFUh|ryP M4XCW|I1KGh? NVrnW3BlTE2VTx?= M4LUVWlv\HWlZYOgZZBweHSxdHnjJIRm[XSq NYj5NZFvOjV6M{S0NFE>
MDA-MB-231 M{TYXmFxd3C2b4Ppd{BCe3OjeR?= NHzIR4c2KM7:TR?= MVyyOEBp MX7EUXNQ NVKwe4hTUW6mdXPld{BieG:ydH;0bYMh\GWjdHi= MXiyOVg{PDRyMR?=
MCF7 MX\GeY5kfGmxbjDBd5NigQ>? M3[4b|Eh|ryP M2Plb|czKGh? MlXISG1UVw>? NWTZbm9HUW6mdXPld{BifXSxcHjh[4lkKGSnYYTo MXWyOVg{PDRyMR?=
MDA-MB-231 NWX2WIZiTnWwY4Tpc44hSXO|YYm= NHzYfJEyKM7:TR?= NFvXWlU4OiCq NHruVYdFVVOR MmDnTY5lfWOnczDheZRweGijZ3njJIRm[XSq NYPqXnE1OjV6M{S0NFE>
U-2 OS NUfxbpNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFK2[Gg2OCEQvF2= M2rPZVI1KGh? MVjEUXNQ MojWTWM2OD1zNj62JO69VQ>? NXnGNJNWOjV5OUK4NVE>
MG-63 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUi5[VhpPTBizszN M{LlNVI1KGh? M3G3U2ROW09? MWnJR|UxRTlwNTFOwG0> MXmyOVc6OjhzMR?=
U-2 OS Mn3YRZBweHSxc3nzJGF{e2G7 MXO1JO69VQ>? M3nYcVI1KGh? M4m3VGROW09? NF3ab2dKdmS3Y3XzJIFxd3C2b4TpZ{Bk\WyuIHTlZZRp M4LpXlI2Pzl{OEGx
MG-63 NH7PWmxCeG:ydH;zbZMhSXO|YYm= MUK1JO69VQ>? NHjlWY4zPCCq NVe1WZlRTE2VTx?= NHO2UJBKdmS3Y3XzJIFxd3C2b4TpZ{Bk\WyuIHTlZZRp Mn3sNlU4QTJ6MUG=
U-2 OS Mme4SpVv[3Srb36gRZN{[Xl? NIHXOYM2KM7:TR?= M2LXSlI1KGh? MWLEUXNQ M2rSXnBzd22xdHXzJIF2fG:yaHHnbYMh[2WubDDk[YF1cA>? M3L0cVI2Pzl{OEGx
MG-63 NEG2dIlHfW6ldHnvckBCe3OjeR?= MYK1JO69VQ>? M3HqW|I1KGh? NHPQdJdFVVOR M3rnbXBzd22xdHXzJIF2fG:yaHHnbYMh[2WubDDk[YF1cA>? M4fHS|I2Pzl{OEGx
PANC-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHKxO2c2OCEQvF2= M13YZVI1KGh? MUXEUXNQ Mnn5TWM2OD15LkGg{txO MWqyOVY{OjJ{NR?=
BxPC-3 NUj5SJFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkj1OVAh|ryP MoLuNlQhcA>? MUDEUXNQ MXvJR|UxRTZwODFOwG0> NFXDV4QzPTZ|MkKyOS=>
PANC-1 NGjLeFRHfW6ldHnvckBCe3OjeR?= M4PR[|Uh|ryP M2HTd|I1KGh? MX\EUXNQ M{HEOWlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgbY4hTzJxTTDwbIF{\Q>? MoG5NlU3OzJ{MkW=
BxPC-3 NGK5T3lHfW6ldHnvckBCe3OjeR?= NUfpXZR{PSEQvF2= NUfkd|RSOjRiaB?= MXHEUXNQ MYnJcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHnuJGczN01icHjhd4U> MYKyOVY{OjJ{NR?=
PANC-1 NF;PSGpHfW6ldHnvckBCe3OjeR?= NGi4[HY2KM7:TR?= M1y0N|I1KGh? MV\EUXNQ MV7JcoR2[2W|IHH1eI9xcGGpaXOgZ4VtdCCmZXH0bC=> M{X1RlI2PjN{MkK1
BxPC-3 M1TDNWZ2dmO2aX;uJGF{e2G7 MXq1JO69VQ>? MX6yOEBp M4PUfWROW09? NGnuc|hKdmS3Y3XzJIF2fG:yaHHnbYMh[2WubDDk[YF1cA>? Mnq0NlU3OzJ{MkW=
SKOV3 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYixNFAh|ryP MmHRNlQhcA>? MkLrSG1UVw>? M4Xi[2lEPTB;MkCuOFgh|ryP NYDWclNMOjV4MkS3OVA>
OVCAR4 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TxXVExOCEQvF2= MlS4NlQhcA>? NFG2[2pFVVOR MmjiTWM2OD1{Mj6xN{DPxE1? M2PleVI2PjJ2N{Ww
SKOV3 NUTrU4trTnWwY4Tpc44hSXO|YYm= NF;kZZM2KM7:TR?= NHzxc2w4OiCq M4rR[mROW09? MXnJcoR2[2W|IFeyM20h[XK{ZYP0 MnjaNlU3OjR5NUC=
OVCAR4 MXLGeY5kfGmxbjDBd5NigQ>? M1HGdVUh|ryP MX23NkBp NY[5SI1zTE2VTx?= NF71UodKdmS3Y3XzJGczN01iYYLy[ZN1 MXSyOVYzPDd3MB?=
SKOV3 MV\BdI9xfG:|aYOgRZN{[Xl? NHey[YY2KM7:TR?= M2ja[FI1KGh? NF[zcZpFVVOR Mnu0TY5lfWOnczDhdI9xfG:|aYO= MX[yOVYzPDd3MB?=
OVCAR4 NYj0RZR[SXCxcITvd4l{KEG|c3H5 NH\MWlA2KM7:TR?= MUeyOEBp NFTBbZZFVVOR M4DCPGlv\HWlZYOgZZBweHSxc3nz MmnsNlU3OjR5NUC=
AGS MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHLZmp3OjVizszN NGrhXJMzPCCq M4fa[2ROW09? NIDUbVhKSzVyPUG5MlA6KM7:TR?= NEX6dI8zPTZyOUmyNy=>
NCI-N78 Mn7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTENlUh|ryP MmPnNlQhcA>? Mn3pSG1UVw>? MmPQTWM2OD1{Nj6zN{DPxE1? MlHWNlU3ODl7MkO=
AGS NHrmcXNCeG:ydH;zbZMhSXO|YYm= MkPxOUDPxE1? M1;yN|I1KGh? Mnq3SG1UVw>? NVfjc49jUW6mdXPld{BieG:ydH;zbZM> MVqyOVYxQTl{Mx?=
NCI-N78 Mnu1RZBweHSxc3nzJGF{e2G7 Mk[0OUDPxE1? MUWyOEBp M1HpNmROW09? NGK4fIZKdmS3Y3XzJIFxd3C2b4Ppdy=> MkPVNlU3ODl7MkO=
AGS NHnaeXFHfW6ldHnvckBCe3OjeR?= NHXL[pM2KM7:TR?= MVqyOEBp M4TsU2ROW09? NIKwc4dKdmS3Y3XzJJRp\SCjdYTvdIhi\3l? M{ntT|I2PjB7OUKz
NCI-N78 MYPGeY5kfGmxbjDBd5NigQ>? M4jWVlUh|ryP MkfjNlQhcA>? NV;oT|VkTE2VTx?= Mn34TY5lfWOnczD0bIUh[XW2b4DoZYd6 M17uOVI2PjB7OUKz
HSC-3 NGq0R45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PnOlEh|ryP MkfyOFghcA>? NFG4XWlKSzVyPUCuOVQh|ryP M{n1W|I2OzZ4MUSz
GB30 MnfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDmZ4cyKM7:TR?= M2[zeVch\A>? NXfvdHp5TE2VTx?= MmfTTWM2OD1yLkCxNUDPxE1? M2C2O|I2OTB4NEK4
GB9 M1XKemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXVSGRwOSEQvF2= Ml\JO{Bl M4LYcGROW09? NXXXcpJyUUN3ME2wMlAzPCEQvF2= Mo\ENlUyODZ2Mki=
GB169 MmnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVixJO69VQ>? NH;QZXE4KGR? M{PIUGROW09? M3TncGlEPTB;MD6wN|Ih|ryP MUOyOVExPjR{OB?=
T24 MnfoSpVv[3Srb36gRZN{[Xl? MXSxJO69VQ>? MmTyOFghcA>? M2jId2ROW09? M2XlUWlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S= MlS3NlM1ODN4M{O=
RT4 NF3iOGFHfW6ldHnvckBCe3OjeR?= M4rVelEh|ryP NEXvSmw1QCCq NXnmS4FzTE2VTx?= MX\JcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2 NWnRVGhTOjN2MEO2N|M>
UM-UC-3 MkDiSpVv[3Srb36gRZN{[Xl? NIfyfZUyKM7:TR?= M4rm[|Q5KGh? NEDvWG9FVVOR MU\JcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2 M13VUFI{PDB|NkOz
T24 NHXvc3VCeG:ydH;zbZMhSXO|YYm= M2PhWlMvOTZizszN MoToPVYhcA>? Mn\tSG1UVw>? NFL4eo9KSzVyPUCuNFMxPiEQvF2= NXXHc5ZJOjN2MEO2N|M>
RT4 NG\RXGRCeG:ydH;zbZMhSXO|YYm= NFzpc20{NjF4IN88US=> M{ixRlk3KGh? M3P4ZWROW09? M3;GcGlEPTB;MD6xNVk5KM7:TR?= M1HQ[FI{PDB|NkOz
UM-UC-3 NUn6bmljSXCxcITvd4l{KEG|c3H5 MXOzMlE3KM7:TR?= MWe5OkBp NEHudIdFVVOR MVPJR|UxRTBwMES0PUDPxE1? MWSyN|QxOzZ|Mx?=
OVCAR-5 MYHGeY5kfGmxbjDBd5NigQ>? NVrzRZlVPTBibl2= MmOzTY5pcWKrdIOgZ4VtdCCvaXfyZZRqd25? NYXEe2tNOjN|M{SzNlc>
SKOV3ip2 NXvrfJlwTnWwY4Tpc44hSXO|YYm= NHf3Nlk2OCCwTR?= NV3pdZdDUW6qaXLpeJMh[2WubDDtbYdz[XSrb36= MX:yN|M{PDN{Nx?=
S462 MnfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYixNFAh|ryP NGrKOmk4OiCq MWrEUXNQ NIHYcWJCfHSnboXheIV{KGOnbHyg[5Jwf3Sq NHXyTGwzOzN{OEGxOC=>
2884 MmjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4L0dlExOCEQvF2= NU\lXJVbPzJiaB?= MWTEUXNQ MnLQRZR1\W63YYTld{Bk\WyuIHfyc5d1cA>? M4rnTVI{OzJ6MUG0
2885 NV3TfHZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;aS2YyODBizszN M1jEe|czKGh? NE\WRmtFVVOR NVXDVHZqSXS2ZX71ZZRmeyClZXzsJIdzd3e2aB?= M1H1c|I{OzJ6MUG0
CRL-2396 NGX4bGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTC[lg2OTByIN88US=> NFHVWFd4[XSnch?= MYnJR|UxRTBwMEmyJO69VQ>? NXLXNHk5OjNzNUO1NlQ>
TIB-48 NIWx[XZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfVSmtJOTByIN88US=> MmnOe4F1\XJ? MVjJR|UxRTBwMEi4JO69VQ>? NXPX[HVEOjNzNUO1NlQ>
CRL-2396 NGPxfmVEgXSxdH;4bYMhSXO|YYm= M4r1T|Eh|ryP MUC0PEBp NWL3TWdnf2G2ZYK= M4HKd2lv\HWlZYOgZZBweHSxc3nz MV2yN|E2OzV{NB?=
TIB-48 MUDDfZRwfG:6aXOgRZN{[Xl? NFe1WncyKM7:TR?= Mn7iOFghcA>? M2npdJdifGW{ M{DxeWlv\HWlZYOgZZBweHSxc3nz MWqyN|E2OzV{NB?=
AGS M1TuRWN6fG:2b4jpZ{BCe3OjeR?= NH7zRYMxNjVizszN NF3pT2MzPCCq NFjNUnpFVVOR NEnmO|BF\WO{ZXHz[ZMh[2WubDDzeZJ3cX[jbB?= MkPNNlI6PzJ4MUG=
FLO-1 NIe3dWNEgXSxdH;4bYMhSXO|YYm= M{\LR|AvPSEQvF2= MWiyOEBp NX;yWnB3TE2VTx?= M1\BTmRm[3KnYYPld{Bk\WyuIIP1dpZqfmGu M3jBNFIzQTd{NkGx
OE33 M2WybWN6fG:2b4jpZ{BCe3OjeR?= MoOxNE42KM7:TR?= MUCyOEBp NEf0WFJFVVOR MVrE[YNz\WG|ZYOgZ4VtdCC|dYL2bZZidA>? NGHWeXQzOjl5Mk[xNS=>
SKLMS MVTDfZRwfG:6aXOgRZN{[Xl? M4LjSlc2KG6P MYK5OkBp NX;6dotvUW6mdXPld{BieG:ydH;zbZM> MUGyNlgzOTl7Nx?=
Leio285 M1nCc2N6fG:2b4jpZ{BCe3OjeR?= NF\rTHc4PSCwTR?= MlT4PVYhcA>? M3;wU2lv\HWlZYOgZZBweHSxc3nz M2XTUlIzQDJzOUm3
Mes-Sa NXL2S3Q{S3m2b4TvfIlkKEG|c3H5 NYTPd5ZvPzVibl2= NIDjToU6PiCq MVzJcoR2[2W|IHHwc5B1d3Orcx?= NHjv[oEzOjh{MUm5Oy=>
DAOY MY\DfZRwfG:6aXOgRZN{[Xl? M4jVflExKM7:TR?= M4faU|czKGh? NF;VfINFVVOR M1L4PWlEPTB;MD6wOEDPxE1? M3;kN|IzPjZ7M{O1
IMR32 NYX3fFd3S3m2b4TvfIlkKEG|c3H5 MX2xNEDPxE1? M4HJW|czKGh? MlPpSG1UVw>? NX7pXndPUUN3ME2wMlA{KM7:TR?= M17Ld|IzPjZ7M{O1
Molt-4 MYjDfZRwfG:6aXOgRZN{[Xl? NULRcVhKOTBizszN MkLNO|IhcA>? NUHoVVRLTE2VTx?= NXTLcm57UUN3ME2wMlAzKM7:TR?= M2HVZVIzPjZ7M{O1
MOLM-13 NHr1dYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXRdoJVOyEQvF2= NHHzdGQ4OiCq M1;NT2RqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm= NFPvO|czOjR6OEK0PS=>
HL-60 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUSzJO69VQ>? Mn7nO|IhcA>? MVLEbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 M3vtUVIzPDh6MkS5
MV4-11 NFezNnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33KNFMh|ryP NYTNV5hZPzJiaB?= NV\QZ2h4TGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=> MlvYNlI1QDh{NEm=
SKM-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PiflMh|ryP NWTTPIVpPzJiaB?= Ml;ZSIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?= NFq1XGQzOjR6OEK0PS=>
SH2 NYXsUVF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWGzJO69VQ>? NGLXcYs4OiCq NGq2eoJFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5 MUiyNlQ5QDJ2OR?=
NOMO-1 M3zwSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml60N{DPxE1? M13UblczKGh? MWLEbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 MY[yNlQ5QDJ2OR?=
OCL-AML2 NFPDdoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrtN|VZOyEQvF2= MmDtO|IhcA>? MoGwSIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?= NXr5bI1DOjJ2OEiyOFk>
PL-21 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nrR|Mh|ryP Ml7QO|IhcA>? Mor6SIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?= M4TPVlIzPDh6MkS5
KG-1 Mnn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPR[2tLOyEQvF2= NULQR|VkPzJiaB?= NYDYO451TGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=> NIjPS5AzOjR6OEK0PS=>
A172 MoW3R5l1d3SxeHnjJGF{e2G7 NWXYR5N{OTByIN88US=> MVqyOEBp NGT3Z2FFVVOR NIizWldKSzVyPUCuNVIxKM7:TR?= M1i3fFIzOjd2M{m5
U87 MVnDfZRwfG:6aXOgRZN{[Xl? MVKxNFAh|ryP MYqyOEBp NFHSdnpFVVOR NEThVI5KSzVyPUCuNVA2KM7:TR?= M1nm[lIzOjd2M{m5
U251 NHT3N|BEgXSxdH;4bYMhSXO|YYm= Mn3BNVAxKM7:TR?= MnTYNlQhcA>? M{jxPGROW09? NUXEWplwUUN3ME2wMlExOCEQvF2= MoDtNlIzPzR|OUm=
T98 M3TFPWN6fG:2b4jpZ{BCe3OjeR?= M{ToVFExOCEQvF2= M{TsclI1KGh? MmjpSG1UVw>? Mn\KTWM2OD1yLkGyOUDPxE1? MXmyNlI4PDN7OR?=
LN18 NXHnfGltS3m2b4TvfIlkKEG|c3H5 MW[xNFAh|ryP MV2yOEBp NI\jOllFVVOR MVHJR|UxRTBwMkGwJO69VQ>? NUDpN2VjOjJ{N{SzPVk>
LN443 NXXpXnNkS3m2b4TvfIlkKEG|c3H5 M37xT|ExOCEQvF2= M1u3eFI1KGh? NGrG[IZFVVOR NITxVYpKSzVyPUCuNlIxKM7:TR?= M2\PWVIzOjd2M{m5
HF66 NELUSphEgXSxdH;4bYMhSXO|YYm= MXSxNFAh|ryP NVu1eI9bOjRiaB?= MoXzSG1UVw>? MXfJR|UxRTBwMkK1JO69VQ>? M{HvU|IzOjd2M{m5
HF2303 NIXXVVlEgXSxdH;4bYMhSXO|YYm= M4qycVExOCEQvF2= NVjUTpR3OjRiaB?= M{L3cGROW09? M3\VTGlEPTB;MD6wOlAh|ryP NX3xXFhIOjJ{N{SzPVk>
HF2359 MoPqR5l1d3SxeHnjJGF{e2G7 NHjzTnAyODBizszN MWWyOEBp NUizdlJLTE2VTx?= MVrJR|UxRTBwME[wJO69VQ>? NEnZNGczOjJ5NEO5PS=>
HF2414 MkS5R5l1d3SxeHnjJGF{e2G7 NF\0d|UyODBizszN MVuyOEBp NHvwXHVFVVOR NWTZXI9[UUN3ME2wMlA5OCEQvF2= NYTFNHpQOjJ{N{SzPVk>
A-673 NVL5clJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrCXpcyOCEQvF2= NETQbZA6PiCq MUfEUXNQ MofSTWM2OD1yLkCzNkDPxE1? NFzuXWozOTR2OEW5NS=>
TC-32 NGn5NY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXvNVAh|ryP NUXQfJpuQTZiaB?= MonDSG1UVw>? MYnJR|UxRTBwMEO5JO69VQ>? Mn\KNlE1PDh3OUG=
TC-71 MnWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmOxNVAh|ryP NFztblg6PiCq M{XjXWROW09? MnzjTWM2OD1yLkGwNkDPxE1? MX2yNVQ1QDV7MR?=
SK-N-MC NYf5PG5oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1P2b|ExKM7:TR?= MnXpPVYhcA>? Ml7ZSG1UVw>? Mmm4TWM2OD1yLkC3NkDPxE1? NXOwd5hTOjF2NEi1PVE>
CHLA-9 NYD1[lFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTpTYIyOCEQvF2= NWrlO45zQTZiaB?= NHnlWW9FVVOR NGrPNJVKSzVyPUCuNFE5KM7:TR?= MkP3NlE1PDh3OUG=
CHLA-10 MkLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnofGwyOCEQvF2= M1vvT|k3KGh? M2m1WGROW09? MXnJR|UxRTBwME[wJO69VQ>? MX2yNVQ1QDV7MR?=
CHLA-25 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XzVFExKM7:TR?= NGLub2o6PiCq MUDEUXNQ M4j0TGlEPTB;MD6xOlgh|ryP NHqxcGMzOTR2OEW5NS=>
CHLA-32 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPrfZpIOTBizszN Ml7yPVYhcA>? NGXpdFBFVVOR MV7JR|UxRTBwMUO2JO69VQ>? NV:zPFd4OjF2NEi1PVE>
CHLA-56 NE\FboNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIj1Uo4yOCEQvF2= MXm5OkBp MVfEUXNQ NUXqeotTUUN3ME2xNEDPxE1? M3ezW|IyPDR6NUmx
CHLA-258 NFfDb3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\SNVAh|ryP MVm5OkBp M{\uT2ROW09? NYHR[ZY4UUN3ME2wMlE{OiEQvF2= M4Dx[VIyPDR6NUmx
COG-E-352 NFPCbINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{exdVExKM7:TR?= M3LKbVk3KGh? NV:2U20xTE2VTx?= NF;6TmlKSzVyPUCuNFQ{KM7:TR?= MUWyNVQ1QDV7MR?=
CHLA-90 M3Xofmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWKxNEDPxE1? NGL0NoU6PiCq NFnzSnRFVVOR NGG4b49KSzVyPUCuNFYyKM7:TR?= MWqyNVQ1QDV7MR?=
CHLA-119 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHK3fnkyOCEQvF2= MnOyPVYhcA>? NXPNT5dDTE2VTx?= NYf1[HlLUUN3ME2wMlAzOiEQvF2= M{\rVVIyPDR6NUmx
CHLA-122 NGP6OolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV6xNEDPxE1? NH2ySpM6PiCq M1f4eGROW09? NULJNlFvUUN3ME2wMlAyQSEQvF2= M4r0fVIyPDR6NUmx
CHLA-136 M2XISGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rEZ|ExKM7:TR?= MWq5OkBp NVe3eYtETE2VTx?= MlHiTWM2OD1yLkCzPUDPxE1? MoDqNlE1PDh3OUG=
CHLA-140 M4DKeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYiwOXR1OTBizszN MnvxPVYhcA>? MWfEUXNQ M1HnfWlEPTB;MD6wNlYh|ryP M1K4e|IyPDR6NUmx
LA-N-6 M3;k[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7NXo8yOCEQvF2= MVy5OkBp MYLEUXNQ M{PrWmlEPTB;MD6wOVQh|ryP MXOyNVQ1QDV7MR?=
NB-1643 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfiN|YyOCEQvF2= MlzzPVYhcA>? NYnZXolvTE2VTx?= M4fYRWlEPTB;MD6wN|ch|ryP MoTiNlE1PDh3OUG=
NB-EBc1 NWfJ[mF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfIZ|EyOCEQvF2= Ml;LPVYhcA>? NYjPb5pHTE2VTx?= NGLzbmhKSzVyPUCuNFUxKM7:TR?= NEjienczOTR2OEW5NS=>
SK-N-BE-1 NWTqRVZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX34fnd[OTBizszN MVO5OkBp MlXRSG1UVw>? NUTMNVJHUUN3ME2wMlAzQCEQvF2= Mmm5NlE1PDh3OUG=
SK-N-BE-2 MoXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrFXoVUOTBizszN M3P5UVk3KGh? Mny4SG1UVw>? NX36VmxjUUN3ME2wMlA{PiEQvF2= MUKyNVQ1QDV7MR?=
SMS-KAN M4PWTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXKNVAh|ryP NXnqVYJsQTZiaB?= M4X2OWROW09? MUXJR|UxRTBwMEO0JO69VQ>? NHnie3gzOTR2OEW5NS=>
SMS-KANR Mm\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYGxNEDPxE1? NHfQbok6PiCq MWrEUXNQ MnfJTWM2OD1yLkCyOkDPxE1? MlrFNlE1PDh3OUG=
SMS-KCN MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX6zUZFsOTBizszN MlvTPVYhcA>? NYnKeGRzTE2VTx?= MmLKTWM2OD1yLkCxPUDPxE1? MVWyNVQ1QDV7MR?=
SMS-KCNR MonGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M162T|ExKM7:TR?= NXPac|FlQTZiaB?= NWLW[oEyTE2VTx?= MoX0TWM2OD1yLkCxNEDPxE1? NV7lc2VYOjF2NEi1PVE>
SMS-LHN M3vuWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3VbZIyOCEQvF2= NHy3WYg6PiCq M4n5ZWROW09? NYLhbnNIUUN3ME2wMlA{OiEQvF2= M3TZV|IyPDR6NUmx
SMS-MSN NFryOppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkP2NVAh|ryP NHr6W2g6PiCq NVTsfXg2TE2VTx?= MVPJR|UxRTBwMEKyJO69VQ>? M4G3VFIyPDR6NUmx
SMS-SAN Mnj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17rdVExKM7:TR?= MYO5OkBp NH\FfGlFVVOR NVz1[4xPUUN3ME2wMlAzOCEQvF2= MoDuNlE1PDh3OUG=
Granta-4 NUDHdFFYS3m2b4TvfIlkKEG|c3H5 M4D2V|ExKM7:TR?= M1PKXFch\A>? NF\5UoZKSzVyPUCuNFQxKM7:TR?= MXOyNVI6OTh4Nx?=
DB NFzO[JpEgXSxdH;4bYMhSXO|YYm= NHv1T5IyOCEQvF2= MU[3JIQ> MXTJR|UxRTBwMESyJO69VQ>? Ml3NNlEzQTF6Nke=
RL M3;TRWN6fG:2b4jpZ{BCe3OjeR?= M{\2RVExKM7:TR?= NYjSR|BwPyCm MV3JR|UxRTBwMEG1JO69VQ>? NVP6TmkyOjF{OUG4Olc>
K562 NH7KZpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETESpYyOCEQvF2= NHixPYE6PiCq MX\JR|UxRTBwMEi3JO69VQ>? NGPGcFAzOTB7MU[zNy=>
LAMA-84 M4T3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3X0flExKM7:TR?= NIfPWZk6PiCq NGe2T3JKSzVyPUCuNFU4KM7:TR?= NUjBPVV[OjFyOUG2N|M>
MM15 NUC5NFdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVG0JO69VQ>? NXnBRWFlPzJiaB?= MYHEUXNQ NYP3eXk1UUN3ME2wMlE{KM7:TR?= MUiyNFM5Ojh2NB?=
OPM1 NX\1blVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moj1OEDPxE1? MVy3NkBp Mn24SG1UVw>? NHnEVXdKSzVyPUCuNFMh|ryP MXyyNFM5Ojh2NB?=
RPM1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7CZW1YPCEQvF2= MnrWO|IhcA>? MkCzSG1UVw>? M{\wfGlEPTB;MUCuN|Ih|ryP MXeyNFM5Ojh2NB?=
INA6 NWLifo4xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX[0JO69VQ>? M4LOU|czKGh? MYDEUXNQ MlHWTWM2OD1yLkCwNkDPxE1? NFGwbHkzODN6Mki0OC=>
OPM2 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPaSHoxPCEQvF2= NVXwe3ZyPzJiaB?= M4jpdWROW09? MXnJR|UxRTRwM{eg{txO NV7IRnU5OjB|OEK4OFQ>
MM1R MlTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXflUVB5PCEQvF2= MnvXO|IhcA>? NGjMN21FVVOR NG\Ucm5KSzVyPUGuOlgh|ryP NGeyc5EzODN6Mki0OC=>
DOX40 MnfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4e0dVQh|ryP NHnK[ZE4OiCq MXjEUXNQ M2\rUGlEPTB;NT60PEDPxE1? NVTVcVVHOjB|OEK4OFQ>
LR5 NHzlZWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUX0NlhFPCEQvF2= Moi4O|IhcA>? NXKwUHZFTE2VTx?= M4n2TWlEPTB;Mj61N{DPxE1? M1XDUlIxOzh{OES0
U266 NFjyXmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1Hn[FQh|ryP NFHXOVE4OiCq MUDEUXNQ MmSwTWM2OD1zLkSzJO69VQ>? MVKyNFM5Ojh2NB?=
RD MmHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnWdHFIOTBizszN MVK5OkBp NEDyd2NKSzVyPUCuNlI5KM7:TR?= NVzNeGkxOjBzMEizN|g>
Rh41 M2rK[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPMVnNJOTBizszN M2\tdlk3KGh? MVjJR|UxRTBwMEmwJO69VQ>? Mk\mNlAyODh|M{i=
Rh30 Ml7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWKxNEDPxE1? NGHjc4U6PiCq M33NUGlEPTB;MD6yN|Ah|ryP MlXUNlAyODh|M{i=
BT-12 NFnQZ4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\YO3I2OTBizszN NWrCXJJlQTZiaB?= NWjIfYxmUUN3ME2wMlA3OCEQvF2= MnXrNlAyODh|M{i=
CHLA-266 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXuxNEDPxE1? MXK5OkBp NV\leI5[UUN3ME2wMlA4OiEQvF2= MkezNlAyODh|M{i=
TC-71 M2Cyd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzsNVAh|ryP MYW5OkBp NHvPemRKSzVyPUCuNVAzKM7:TR?= M4PVPVIxOTB6M{O4
SJ-GBM2 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUWxNEDPxE1? MoDDPVYhcA>? NFrDfoVKSzVyPUCuNFUxKM7:TR?= M1vQS|IxOTB6M{O4
NALM-6 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWexNEDPxE1? MWS5OkBp NXv3VmxCUUN3ME2wMlA3OiEQvF2= NID6WnkzODFyOEOzPC=>
COG-LL-317 M{jQemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVyxNEDPxE1? M{TjOVk3KGh? M3fKfWlEPTB;MD6wOFch|ryP MWGyNFExQDN|OB?=
RS4-11 MmjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPzSY9bOTBizszN MoTaPVYhcA>? M{fkS2lEPTB;MD6wNVgh|ryP MWiyNFExQDN|OB?=
MOLT-4 M3\oZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPqcYkyOCEQvF2= NV3oR5RrQTZiaB?= MVHJR|UxRTBwMEK2JO69VQ>? NITQcFAzODFyOEOzPC=>
CCRF-CEM NHjrSZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDINVAh|ryP NIf4cHE6PiCq MVfJR|UxRTBwMEm0JO69VQ>? NYHsb|NDOjBzMEizN|g>
Kasumi-1 MkXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjaO4k4OTBizszN MXq5OkBp NVvqcVljUUN3ME2wMlExOyEQvF2= NWXobnpDOjBzMEizN|g>
Karpas-299 M3GzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml32NVAh|ryP MVy5OkBp NH3LXZJKSzVyPUCuNFM5KM7:TR?= MX2yNFExQDN|OB?=
Ramos-RA1 NUnZbYNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13NSVExKM7:TR?= M2K3elk3KGh? M3W0VmlEPTB;MD6xNlch|ryP M1vWZlIxOTB6M{O4

... Click to View More Cell Line Experimental Data

体内研究 MLN8237口服处理,显著降低肿瘤负担,按15 mg/kg 和30 mg/kg剂量处理肿瘤生长抑制率(TGI) 分别为42%和80%,且与对照组相比,延迟小鼠寿命。[2] MLN8237 (30 mg/kg) 与Cisplatin (2 mg/kg) 联用作用于FLO-1移植瘤,与单独用药相比,抗癌活性增强,伴随着Ki-67表达受抑制,细胞核p73蛋白和cleaved caspase 3表达增强。[3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
+ 展开

Aurora A放射性闪光板酶实验:

进行Aurora A放射性闪光板酶实验,测定体外MLN8237抑制程度。在Sf9细胞中表达重组Aurora A,然后使用GST亲和层析进行纯化。Aurora A 肽底物与生物素联合形成生物素-GLRRASLG。在50 mM Hepes (pH 7.5), 10 mM MgCl2, 5 mM DTT, 0.05% Tween-20, 2 μM 肽底物, 3.3 μCi/mL [γ-33 P]ATP 2 μM, 和浓度不断增高的MLN8237 的混合物中进行Aurora A激酶 (5 nM)实验。
细胞实验:[2]
+ 展开
  • Cell lines: MM1.S, MM.1R, LR5, RPMI 8226, DOX40, OPM1, OPM2, INA6, 和U266
  • Concentrations: 溶于DMSO,终浓度为~10 μM
  • Incubation Time: 24, 48, 和72小时
  • Method: 使用不同浓度MLN8237处理细胞24, 48,和72小时。通过MTT实验测定细胞活力,通过测定 3[3H]-胸甘渗透而测定细胞增殖。为了分析细胞周期,使用70%乙醇在-20oC下使细胞通透,然后与50 μg/mL PI 和20 单位/mL RNase-A温育。 通过流式细胞仪使用 BDFACS-Canto II和FlowJo软件分析DNA含量。 为了测定凋亡和衰老,使用异硫氰酸荧光素-annexin V和PI对细胞进行染色。通过流式细胞仪使用 BDFACS-Canto II和FlowJo软件测定凋亡细胞。
    (Only for Reference)
动物实验:[2]
+ 展开
  • Animal Models: 皮下接种 MM1.S 细胞的SCID鼠
  • Formulation: 在10% 2-羟丙基-β-环糊精/1%碳酸氢钠中配制
  • Dosages: ~30 mg/kg/day
  • Administration: 口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 27 mg/mL (52.03 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5%DMSO+30% PEG300+5%Tween-80+ddH2O
8mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 518.92
化学式

C27H20ClFN4O4

CAS号 1028486-01-2
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02860000 Recruiting Estrogen Receptor Status|HER2/Neu Negative|Invasive Breast Carcinoma|Postmenopausal|Stage III Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer Mayo Clinic|National Cancer Institute (NCI) July 6 2017 Phase 2
NCT02860000 Recruiting Estrogen Receptor Status|HER2/Neu Negative|Invasive Breast Carcinoma|Postmenopausal|Stage III Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer Mayo Clinic|National Cancer Institute (NCI) July 6 2017 Phase 2
NCT02700022 Terminated Diffuse Large B-cell Lymphoma|Follicular Lymphoma|Burkitt Lymphoma UNC Lineberger Comprehensive Cancer Center|Millennium Pharmaceuticals Inc. October 2016 Phase 1
NCT02700022 Terminated Diffuse Large B-cell Lymphoma|Follicular Lymphoma|Burkitt Lymphoma UNC Lineberger Comprehensive Cancer Center|Millennium Pharmaceuticals Inc. October 2016 Phase 1
NCT02812056 Withdrawn Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Male Genital Organs M.D. Anderson Cancer Center|Millennium Pharmaceuticals Inc. September 2016 Phase 1
NCT02812056 Withdrawn Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Male Genital Organs M.D. Anderson Cancer Center|Millennium Pharmaceuticals Inc. September 2016 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    What is the suggested formulation of this compound for mouse injection(i.p.)?

  • 回答:

    It can be dissolved in 6% DMSO/50% PEG 300/5% Tween 80/ddH2O at 10 mg/ml as a clear solution.

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

相关Aurora Kinase产品

Tags: 购买Alisertib (MLN8237) | Alisertib (MLN8237)供应商 | 采购Alisertib (MLN8237) | Alisertib (MLN8237)价格 | Alisertib (MLN8237)生产 | 订购Alisertib (MLN8237) | Alisertib (MLN8237)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID